Biological predictors of survival in stage II colorectal cancer

Ueda,Yoshitake; Yasuda,Kazuhiro; Inomata,Masafumi; Shiraishi,Norio; Yokoyama,Shigeo; Kitano,Seigo

doi:10.3892/mco.2013.126

Biological predictors of survival in stage II colorectal cancer

Authors:
- Yoshitake Ueda
- Kazuhiro Yasuda
- Masafumi Inomata
- Norio Shiraishi
- Shigeo Yokoyama
- Seigo Kitano
View Affiliations

Affiliations: Department of Gastroenterological Surgery, Faculty of Medicine, Oita University, Yufu, Oita 879‑5593, Japan, Department of Pathology, Faculty of Medicine, Oita University, Yufu, Oita 879‑5593, Japan, Oita University, Yufu, Oita 879‑5593, Japan
Published online on: May 20, 2013 https://doi.org/10.3892/mco.2013.126
Pages: 643-648

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The routine use of postoperative adjuvant chemotherapy in patients with stage II colorectal cancer is not recommended. However, the incidence of tumor recurrence or distant metastasis in these patients is reported to be 25‑35%. The identification of high‑risk patients with stage II colorectal cancer remains difficult. Therefore, the aim of this study was to determine the risk factors that may help identify stage II colorectal cancer patients with unfavorable prognosis. Paraffin‑embedded tissue samples from 109 patients with stage II colorectal cancer following curative operation were analyzed. Thirteen clinicopathological variables and 5 biological markers were assessed using immunohistochemistry, including p53 (tumor suppressor gene), CD10 (tumor invasion marker), CD34 (angiogenic marker), Ki‑67 (cell proliferation index) and CAM 5.2 (marker of lymph node micrometastasis) and investigated for associations with disease‑specific survival. Univariate analysis revealed bowel obstruction, lymph node micrometastasis and lymphatic invasion (P<0.01) to be highly significant factors for determining the 5‑year disease‑specific survival. By contrast, the multivariate analysis revealed lymph node micrometastasis and lymphatic invasion to be independent prognostic factors. Stage II colorectal cancer patients with lymph node micrometastasis and lymphatic invasion may therefore be suitable candidates for adjuvant chemotherapy to improve prognosis.

View Figures

View References

1.	Jemal A, Siegel R, Ward EA, et al: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar
2.	Graziano F and Cascinu S: Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes’ B colorectal cancer patients: how much evidence is enough? Ann Oncol. 14:1026–1038. 2003.PubMed/NCBI
3.	Allegra CJ, Paik S, Colangelo LH, et al: Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes’ B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol. 21:241–250. 2003.
4.	Garrity MM, Burgart LJ, Mahoney MR, et al: Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes’ B2 or C colon cancer: a North Central Cancer Treatment Group Study. J Clin Oncol. 22:1572–1582. 2004.PubMed/NCBI
5.	Bhatavdekar JM, Patel DD, Chikhlikar PR, et al: Molecular markers are predictors of recurrence and survival in patients with Dukes B and Dukes C colorectal adenocarcinoma. Dis Colon Rectum. 44:523–533. 2001. View Article : Google Scholar : PubMed/NCBI
6.	Gervaz P, Cerottini JP, Bouzourene H, et al: Comparison of microsatellite instability and chromosomal instability in predicting survival of patients with T3N0 colorectal cancer. Surgery. 131:190–197. 2002. View Article : Google Scholar : PubMed/NCBI
7.	Sinicrope FA, Hart J, Hsu HA, et al: Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas. Clin Cancer Res. 5:1793–1804. 1999.PubMed/NCBI
8.	Kim YH, Lee JH, Chun H, et al: Apoptosis and its correlation with proliferative activity in rectal cancer. J Surg Oncol. 79:236–242. 2002. View Article : Google Scholar : PubMed/NCBI
9.	Sadahiro S, Suzuki T, Maeda Y, et al: Predictors of tumor downsizing and regression with preoperative radiotherapy alone and with concomitant tegafur/uracil (UFT) for resectable advanced rectal adenocarcinoma. Hepatogastroenterology. 54:1107–1112. 2007.
10.	Fujimoto Y, Nakanishi Y, Sekine S, et al: CD10 expression in colorectal carcinoma correlates with liver metastasis. Dis Colon Rectum. 48:1883–1889. 2005. View Article : Google Scholar : PubMed/NCBI
11.	Ogawa H, Iwaya K, Izumi M, et al: Expression of CD10 by stromal cells during colorectal tumor development. Hum Pathol. 33:806–811. 2002. View Article : Google Scholar : PubMed/NCBI
12.	Weber JC, Nakano H, Bachellier P, et al: Is a proliferation index of cancer cells a reliable prognostic factor after hepatectomy in patients with colorectal liver metastases? Am J Surg. 182:81–88. 2001. View Article : Google Scholar : PubMed/NCBI
13.	Ueno H, Price AB, Wilkinson KH, et al: A new prognostic staging system for rectal cancer. Ann Surg. 240:832–839. 2004. View Article : Google Scholar : PubMed/NCBI
14.	Jass JR, Love SB and Northover JM: A new prognostic classification of rectal cancer. Lancet. 1:1303–1306. 1987. View Article : Google Scholar : PubMed/NCBI
15.	Oh-e H, Tanaka S, Kitadai Y, et al: Angiogenesis at the site of deepest penetration predicts lymph node metastasis of submucosal colorectal cancer. Dis Colon Rectum. 44:1129–1136. 2001. View Article : Google Scholar : PubMed/NCBI
16.	Yasuda K, Adachi Y, Shiraishi N, et al: Pattern of lymph node micrometastasis and prognosis of patients with colorectal cancer. Ann Surg Oncol. 8:300–304. 2001. View Article : Google Scholar : PubMed/NCBI
17.	Okuyama T, Nakamura T and Yamaguchi M: Budding is useful to select high-risk patients in stage II well-differentiated or moderately differentiated colon adenocarcinoma. Dis Colon Rectum. 46:1400–1406. 2003. View Article : Google Scholar : PubMed/NCBI
18.	Feezor RJ, Copeland EM III and Hochwald SN: Significance of micrometastases in colorectal cancer. Ann Surg Oncol. 9:944–953. 2002. View Article : Google Scholar : PubMed/NCBI
19.	Palmqvist R, Sellberg P, Oberg A, et al: Low tumour cell proliferation at the invasive margin is associated with a poor prognosis in Dukes’ stage B colorectal cancers. Br J Cancer. 79:577–581. 1999.PubMed/NCBI
20.	Noura S, Yamamoto H, Miyake Y, et al: Immunohistochemical assessment of localization and frequency of micrometastases in lymph nodes of colorectal cancer. Clin Cancer Res. 8:759–767. 2002.PubMed/NCBI
21.	Bukholm IR, Bondi J, Wiik P, et al: Presence of isolated tumour cells in mesenteric lymph nodes predicts poor prognosis in patients with stage II colon cancer. Eur J Surg Oncol. 29:862–866. 2003. View Article : Google Scholar : PubMed/NCBI
22.	O’Connell MJ, Mailliard JA, Kahn MJ, et al: Controlled trial of fluorouracil and low-dose leucovorin given 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol. 15:246–250. 1997.PubMed/NCBI
23.	Barone C: Adjuvant chemotherapy of colon cancer current strategies. Eur J Cancer. 6:60–63. 2008. View Article : Google Scholar
24.	Van Cutsem E and Costa F: Progress in the adjuvant treatment of colon cancer. Has it influenced clinical practice? JAMA. 7:2758–2760. 2005.PubMed/NCBI
25.	O’Connell MJ: Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: the results are in. J Clin Oncol. 27:3082–3084. 2009.
26.	No authors listed:. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol. 17:1356–1363. 1999.
27.	Figueredo A, Charrette M, Maroun J, et al: Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care’s gastrointestinal cancer disease site group. J Clin Oncol. 22:3395–3407. 2004.
28.	Quasar Collaborative Group; Gray R, Barnwell J, McConkey C, Hills RK, Williams NS and Kerr DJ: Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 370:2020–2029. 2007. View Article : Google Scholar : PubMed/NCBI
29.	Norum J: Adjuvant chemotherapy in Dukes’ B and C colorectal cancer has only a minor influence on psychological distress. Support Care Cancer. 5:318–321. 1997.
30.	Sirop S, Kanaan M, Korant A, et al: Detection and prognostic impact of micrometastasis in colorectal cancer. J Surg Oncol. 103:534–537. 2011. View Article : Google Scholar : PubMed/NCBI